Phase II trial of irinotecan/temozolomide/dinutuximab/granulocyte macrophage colony stimulating factor (I/T/DIN/GMCSF) in children with relapsed/refractory neuroblastoma (NBL): A r... von Mody, Rajen, Naranjo, Arlene, Yu, Alice L., Hibbitts, Emily, London, Wendy B., Shulkin, Barry L., Parisi, Marguerite T, Servaes, Sabah-E-Noor, Dicciani, Mitchell B, Sondel, Paul M., Glade-Bender, Julia, Katzenstein, Howard, Maris, John, Park, Julie R., Bagatell, Rochelle

Volltext

Phase II randomized trial of irinotecan/temozolomide (I/T) with temsirolimus (TEM) or dinutuximab plus granulocyte colony stimulating factor (DIN/GMCSF) in children with refractory... von Mody, Rajen, Naranjo, Arlene, Van Ryn, Collin, Yu, Alice L., London, Wendy B., Shulkin, Barry L., Parisi, Marguerite T, Servaes, Sabah-E-Noor, Dicciani, Mitchell B, Sondel, Paul M., Maris, John M., Park, Julie R., Bagatell, Rochelle

Volltext

Impact of KIR/KIR ligand genotype for neuroblastoma patients in a phase III COG immunotherapy trial von Erbe, Amy K, Wang, Wei, Carmichael, Lakeesha, Kim, KyungMann, Mendonca, Eneida A, Song, Yiqiang, Hess, Dustin, London, Wendy B., Hank, Jacquelyn A, Dicciani, Mitchell B, Reisfeld, Ralph A, Gillies, Stephen D, Hogarty, Michael D., Maris, John M., Park, Julie R., Ozkaynak, Mehmet Fevzi, Gilman, Andrew Lee, Yu, Alice L., Sondel, Paul M.

Volltext